Gyre Therapeutics Inc (GYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 29,105 | 22,519 | 34,232 | 30,564 | 29,734 |
| Cost of Goods | 2,209 | 1,227 | 1,743 | 1,628 | 1,151 |
| Gross Profit | 26,896 | 21,292 | 32,489 | 28,936 | 28,583 |
| Operating Expenses | 41,468 | 30,874 | 28,705 | 22,637 | 30,974 |
| Operating Income | -14,363 | -9,355 | 4,529 | 6,925 | -2,240 |
| Interest Expense | 943 | 0 | 0 | 0 | 488 |
| Other Income | 872 | 118 | -782 | 704 | 1,153 |
| Pre-tax Income | -14,434 | -9,237 | 3,747 | 7,629 | -1,575 |
| Income Tax | -164 | 621 | 1,300 | 1,693 | 662 |
| Net Income Continuous | -14,270 | -9,858 | 2,447 | 5,936 | -2,237 |
| Minority Interests | -3,665 | -1,167 | 4,326 | 2,326 | -2,835 |
| Net Income | $-10,605 | $-8,691 | $-1,879 | $3,610 | $598 |
| EPS Basic Total Ops | -0.12 | -0.10 | 0.01 | 0.04 | -0.02 |
| EPS Basic Continuous Ops | -0.14 | -0.11 | 0.03 | 0.07 | -0.03 |
| EPS Diluted Total Ops | -0.12 | -0.10 | 0.02 | 0.03 | -0.03 |
| EPS Diluted Continuous Ops | -0.14 | -0.11 | 0.03 | 0.06 | -0.03 |
| EPS Diluted Before Non-Recurring Items | -0.12 | -0.08 | 0.04 | 0.05 | 0.02 |
| EBITDA(a) | $-12,890 | $-8,683 | $5,222 | $7,252 | $-1,275 |